STAND Against Emerging Opioids Act

HR 3520, the STAND Against Emerging Opioids Act, adds tianeptine and its similar compounds (including salts, isomers, and analogues) to Schedule III of the federal Controlled Substances Act. This change directly affects individuals who use, distribute, or manufacture tianeptine, placing it under federal regulation similar to other controlled substances. The bill amends the Controlled Substances Act to require federal oversight of tianeptine, effective 90 days after the bill's enactment. This policy change shifts tianeptine from unregulated status to a controlled substance category, impacting its legal availability and use.